Takeda’s first-in-class narcolepsy drug succeeds in two registrational studies
Takeda’s oral orexin agonist has cleared a pair of Phase 3 trials in a sleep disorder, marking the first late-stage win for a drug class …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
